Thomas Ebeling - 08 Jun 2023 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Reporting relationship: Director
Issuer ticker: CGEM
Reported as of: 08 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2023, 17:58:25 UTC
Prior SEC filing: 23 Jun 2022
Next SEC filing: 23 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Jacquelyn Sumer, Attorney-in-Fact

Key filing fact

Thomas Ebeling filed Form 4 for Cullinan Oncology, Inc. (CGEM) on 12 Jun 2023.

Key facts

This page summarizes Thomas Ebeling's Form 4 filing for Cullinan Oncology, Inc. (CGEM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2023, 17:58.

Change

Previous filing in this sequence was filed on 23 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CGEM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +18,450
Change %
Price: $0.000000
Shares after: 18,450
Date: 08 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,450
Exercise price: $13.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option represents a right to purchase a total of 18,450 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 8, 2024 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.